On March 29, 2012, Oracle announced that it has agreed to acquire ClearTrial, a leading provider of cloud-based Clinical Trial Operations and analytics products that make the planning, sourcing, and tracking of clinical projects and financial performance faster and more accurate. Until the transaction closes, Oracle and ClearTrial will continue to operate independently, and it is business as usual.
Biopharmaceutical, medical device and diagnostic companies, as well as contract research organizations (CROs), are faced with the increasing complexity and cost of bringing new therapies to market. Traditional methods of using spreadsheets, generic planning software, and ad hoc planning processes have lead to lengthy planning cycles, inaccurate budgets, and high variances between planned budgets and actual costs.
The combination of Oracle and ClearTrial is expected to deliver the most comprehensive closed-loop clinical trial management offering from planning to payment. ClearTrial's activity-based costing solutions use embedded intelligence based on deep industry expertise to help life sciences companies manage the rising costs and increasing complexities of bringing new therapies to market. Oracle provides integrated clinical development and safety management capabilities that streamline study layout and design, patient data collection and management, clinical study modeling, and full data analysis and reporting. Together, Oracle expects to enable companies to significantly improve their ability to manage clinical trials across geographies, outsourcers, therapeutic areas, and trial phases resulting in a better return on their R&D capital investments.
ClearTrial management and employees are expected to join Oracle as a part of the Oracle Health Sciences global business unit, ensuring the continuity of products and services delivery for ClearTrial customers, and bringing significant domain expertise to Oracle. To learn more about the proposed combination of Oracle and ClearTrial, please visit oracle.com/cleartrial.
We appreciate your continued support.
Neil de Crescenzo
Senior Vice President and General Manager
Oracle Health Sciences
This document is for informational purposes only and may not be incorporated into a contract or agreement.
Cautionary Statement Regarding Forward-Looking Statements
This document contains certain forward-looking statements about Oracle and ClearTrial, including statements that involve risks and uncertainties concerning Oracle's proposed acquisition of ClearTrial, anticipated customer benefits and general business outlook. When used in this document, the words "anticipates", "can", "will", "look forward to", "expected" and similar expressions and any other statements that are not historical facts are intended to identify those assertions as forward-looking statements. Any such statement may be influenced by a variety of factors, many of which are beyond the control of Oracle or ClearTrial that could cause actual outcomes and results to be materially different from those projected, described, expressed or implied in this document due to a number of risks and uncertainties. Potential risks and uncertainties include, among others, the possibility that the transaction will not close or that the closing may be delayed, the anticipated synergies of the combined companies may not be achieved after closing, the combined operations may not be successfully integrated in a timely manner, if at all, general economic conditions in regions in which either company does business, and the possibility that Oracle or ClearTrial may be adversely affected by other economic, business, and/or competitive factors. Accordingly, no assurances can be given that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do so, what impact they will have on the results of operations or financial condition of Oracle or ClearTrial. You are cautioned to not place undue reliance on forward-looking statements, which speak only as of the date of this document. Neither Oracle nor ClearTrial is under any duty to update any of the information in this document.